KPV vs. LL-37

When evaluating KPV versus LL-37 for biological age reduction, the primary consideration is the specific hallmark of aging being targeted. While both compounds offer systemic healthspan benefits, their mechanisms of action are distinct.

When to prioritize KPV:

Select KPV when the primary clinical objective aligns with its core mechanism: derived from alpha-msh; binds mc1r and nf-kb to suppress pro-inflammatory cytokine cascades.. This is particularly relevant for protocols focused on potent anti-inflammatory action, particularly for gut and skin inflammation..

When to prioritize LL-37:

Conversely, LL-37 is the superior choice when targeting human cathelicidin antimicrobial peptide that disrupts bacterial membranes, modulates tlr signaling, and promotes wound healing., making it the preferred agent for antimicrobial action, wound healing, and innate immune activation..